Related Experiment Videos
LDL-cholesterol: a risk factor for coronary artery disease--from epidemiology to clinical trials
1Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA.
Insights
Aggressively treating high LDL cholesterol is crucial for cardiovascular disease patients. Evidence shows lowering LDL cholesterol prevents cardiac events effectively and cost-efficiently.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Preventive Cardiology
Background:
- Elevated LDL cholesterol (LDL-C) is a primary risk factor in cardiovascular disease (CVD) development.
- LDL-C plays a role in all pathophysiological stages of atherosclerosis.
- Longitudinal studies confirm LDL-C's link to CVD incidence, recurrence, and mortality.
Purpose of the Study:
- To emphasize the importance of identifying and aggressively treating elevated LDL cholesterol.
- To provide context for discussing other lipid modification strategies.
Main Methods:
- Review of existing evidence on LDL cholesterol's role in CVD.
- Analysis of clinical trial data and economic evaluations.
Main Results:
- Convincing evidence supports aggressive LDL-C treatment in established CVD.
- Lowering LDL-C in high-risk patients prevents cardiac events.
- Treatment demonstrates excellent cost-effectiveness.
Conclusions:
- Aggressive LDL cholesterol management is paramount in patients with established cardiovascular disease.
- Focusing on LDL-C is essential before considering other lipid modifications.
Abstract:
Discussion of potential strategies to modify lipids and lipoproteins other than low density lipoproteins (LDLs) should first recognize the convincing evidence in favour of the identification and aggressive treatment of elevated LDL cholesterol (LDL-C) levels in patients with established cardiovascular disease. Elevated LDL-C level is one of the few risk factors for which there is evidence of involvement in every pathophysiological step of the development of cardiovascular disease. Longitudinal studies have established the role of LDL-C as a risk factor for cardiovascular disease incidence, recurrence and fatal outcome. Clinical trials and economic analyses have proven that aggressive treatment of elevated LDL-C in patients at high risk can prevent cardiac events with excellent cost effectiveness.